ENTRY       D05446                      Drug
NAME        Pertuzumab (USAN/INN);
            Pertuzumab (genetical recombination) (JAN);
            Perjeta (TN)
PRODUCT     PERJETA (Genentech)
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03158  HER2 inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FD02
            Product: D05446<JP/US>
            Product (mixture): D11934<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody
  DISEASE   Breast cancer (HER2 positive) [DS:H00031]
  TYPE      Monoclonal antibody
TARGET      ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3] [HSA:2064] [KO:K05083]
  PATHWAY   hsa04012(2064)  ErbB signaling pathway
            hsa05200(2064)  Pathways in cancer
            hsa05224(2064)  Breast cancer
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
                 L01FD02 Pertuzumab
                  D05446  Pertuzumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Pertuzumab
                D05446  Pertuzumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D05446  Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03158  HER2 inhibitor
                 D05446  Pertuzumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG03158  HER2 inhibitor
               D05446  Pertuzumab
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3]
                 D05446  Pertuzumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05446
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05446
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05446
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05446
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D05446
DBLINKS     CAS: 380610-27-5
            PubChem: 47207115
///
